Katarina Maloney, Founder & CEO of IQMIND, and James Kelly, Chief Medical Officer of Oragenics, Inc. were interviewed by Roy Kessel of the Sports Philanthropy Network at Super Bowl 59 in New Orleans. They participated as panelists for the Brain Health Summit at Leigh Steinberg’s event, discussing advancements in concussion treatment and brain health. Malone shared her personal experience with brain injury and how her company focuses on electromagnetic brain treatments, while Kelly emphasized the need for better concussion diagnosis and medication development.
Katarina Maloney
As the Founder and CEO of IQMIND, I am honored to lead a global organization that is transforming mental health care and brain performance. At IQMIND, we are committed to delivering innovative solutions that enhance diagnostics, treatment, and cognitive optimization through cutting-edge technology, rigorous clinical research, and strategic partnerships.
About IQMIND
IQMIND is uniquely positioned as a global leader in advancing mental health diagnostics and treatment. Our multidisciplinary team includes world-renowned pioneers such as Dr. Michael Pierce, a certified expert in qEEG diagnostics with nearly 30 years of experience, and Dr. Juri Krupotov, an internationally recognized neuroscientist known for groundbreaking brainwave research. Supported by HBImed, the world’s largest neuroimaging database, our work combines unparalleled expertise with a commitment to innovation and impact.
Key Highlights and Achievements
Global Reach: Operating in over 7,000 clinics across 23 countries, we conduct more than 150,000 brain scans weekly, with CPT codes enabling Medicare reimbursement.
Proven Results: Our technologies and approaches are clinically validated, with studies showing up to a 40% reduction in TBI symptoms, a 95% improvement in depression, and a 70% improvement in ADHD/ADD symptoms.
At IQMIND, our vision is to create a world where mental health care is accessible, effective, and stigma-free, empowering individuals to reach their full cognitive potential. Whether improving recovery outcomes for TBI patients or optimizing the performance of elite athletes, IQMIND is at the forefront of revolutionizing brain health.
James Kelly
Dr. Kelly’s immediate past position was Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology and Physical Medicine and Rehabilitation at the University of Colorado Anschutz Medical Campus in Aurora, CO. The MIBH is a specialized treatment program funded by the Marcus Foundation to care for US military Veterans and First Responders with persistent symptoms of TBI. He was also National Director of the Avalon Network TBI Medical Programs for which the MIBH served as the clinical coordinating center.
Prior to founding the MIBH, he was Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD. As its founding Director, he led the creation of an innovative interdisciplinary team of healthcare professionals who blended high-tech diagnosis and treatment with complementary and alternative medical interventions in a holistic, integrative approach to the care of U.S. military personnel with the complex combination of TBI and psychological conditions such as post-traumatic stress, depression, and anxiety. In this role, Dr. Kelly was frequently called upon by leaders of the Military Health System in the Pentagon, the U.S. Congress, the Department of Veterans Affairs, and numerous military facilities in the continental U.S. and abroad. He twice traveled to Afghanistan to advise and assist at military hospital programs and forward operating base medical units.
Dr. Kelly is President of Kelly Neuroscience Consulting, LLC and co-owner of Valor Industries which manufactures hockey helmets. He holds US patents on helmet liners and the transmission of signals from helmet motion sensors.
IQMIND is revolutionizing the brain health game with cutting-edge, non-invasive neurofeedback (NFB) training. Powered by advanced EEG-based diagnostics and AI-driven innovation, we deliver more than treatment—we optimize lives.
Whether you’re an NFL elite athlete pushing limits or someone overcoming PTSD, ADHD, anxiety, or TBI, IQMIND equips you to unlock your full potential.
As we expand into high-traffic public spaces like malls and airports, we aim to make world-class brain care and human potential affordable and accessible to all.
Oragenics, Inc. is a development-stage company dedicated to developing drugs, therapies and vaccines through intra-nasal delivery. We continue to strengthen our focus and build our expertise around intranasal drug delivery platforms through new strategic partnerships. On December 28, 2023, we closed our asset purchase agreement with Odyssey Health, Inc. to acquire all of their neurology assets related to treating mild traumatic brain injury, also known as concussion and for treating Niemann Pick Disease Type C (ONP-002 and ONP-001). Also included in the assets acquired was their proprietary powder formulation and its nasal delivery device, which Oragenics believes to be novel.
Most recently Oragenics research and development projects were focused on infection diseases including coronaviruses and multidrug-resistant organisms. Oragenics is excited to add a nasal delivery drug product to their portfolio focused on developing a treatment for brain related illness and injury. Following the acquisition of ONP-002 and ONP-001 Oragenics will be focusing efforts in this new important area of treating concussion.
Concussion is an unmet medical need, there is an estimated 69M concussion annually reported worldwide. Other neurological disorders including Alzheimer’s Disease, Parkingson’s Disease, and Chronic Traumatic Encephalopathy (CTE) have been linked to concussions.
Watch the Interview Here
- [00:01] Introduction – Roy Kessel introduces the interview from Radio Row at Super Bowl 59 and welcomes panelists for the **Brain Health Summit** at Leigh Steinberg’s event.
- [00:29] Guest Introductions – Katarina Maloney (IQMIND CEO) and Jim Kelly (Chief Medical Officer, Oragenics, Inc.) introduce themselves and their work in brain health and concussion treatment.
- [01:07] Maloney’s Personal Experience with Brain Injury – Maloney shares how a severe concussion left her struggling with daily tasks, which led her to develop IQMIND’s brain performance solutions.
- [02:19] IQMIND’s Technology – Maloney explains how IQMIND uses electromagnetic brain treatments to improve focus, clarity, concussion symptoms, and sleep, and how they’ve worked with Red Bull athletes.
5. [03:22] The Prevalence of Brain Injuries – Discussion on how concussions happen beyond sports, including car accidents, falls, and everyday incidents, highlighting the need for better brain health solutions.
- [04:38] Expanding Brain Health Treatment – Maloney shares how their technology can help children with ADHD, elderly patients with memory issues, and those struggling with depression or TBIs.
- [05:43] James Kelly’s Career in Brain Injury Research – Kelly discusses his background in neurology, psychology, and behavioral neurology, emphasizing his long-standing work in concussion research since the 1990s.
- [07:30] Oragenics’ Work on Concussion Medication – Kelly highlights the lack of approved concussion medications and Oragenics’ focus on developing treatments for neurological inflammation to improve recovery.
- [09:13] Advances in Brain Injury Diagnosis – Kelly shares insights from his work with the military and sports communities, discussing the challenges in diagnosing and treating concussions effectively.
- [10:53] Closing Remarks – Kessel thanks the panelists, encourages them to participate in the Wall of Philanthropy, and signs off on behalf of the Sports Philanthropy Network.
